Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

Clinical Trials 250

Clinical Trials Chronic Pain Cannabinoids Patients 250

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Patients who met eligibility criteria were able to continue ganaxolone treatment during a 24-week extension to the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. Cannabis has been used medicinally for thousands of years by the human race for a large catalogue of ailments. CONVENTIONAL TREATMENT. Treatment includes surgery and nutritional and lifestyle changes.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Cannabis Law Report

JUNE 2, 2021

The latest article in Healthcare Business Today cites the company’s Multiomics Advanced Technology™ (MAT) as the driver for more accurate predictions about disease states and individual responses to diseases and treatments that will make medicine truly personalized.

Medicine 90

Medicine Business Treatment Data 90

Veriheal

AUGUST 12, 2021

Funded by Realm of Caring —a non-profit organization committed to redefining cannabis through research and education—this study on CBD and epilepsy was carried out as part of a joint effort with Johns Hopkins University School of Medicine researchers. 10 mg/kg/day is the current recommended maintenance dose for pharmaceutical CBD).”.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. There are some other cannabis-based medicines that are licensed in the UK.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

FEBRUARY 21, 2023

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. To explore this issue further, let’s look at the key findings of this groundbreaking new research.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

JANUARY 16, 2022

Ketum is regulated under the Third Schedule of the Poisons Act that regulates drugs and medicines. Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Sensi Seeds

JANUARY 4, 2019

Context of the Medicinal Cannabis Situation. Since 2001, Canadians seeking to use cannabis for medical treatment have had access to it under the Marihuana Medical Access Regulations (MMAR ). Under the regulations, no intermediaries are allowed to sell medicinal cannabis to patients. The Canadian Medical Association (CMA).

Medicine 75

Medicine Research and Development Patients Programs 75

The Joint Blog

NOVEMBER 2, 2020

According to a new study published in the Journal of Pharmacy & Pharmaceutical Sciences, using marijuana as an adjunct treatment for Huntington disease (HD) is both effective and safe. Study selection, quality assessment and data extraction was performed by three reviewers.

Treatment 37

Treatment Sleep Marijuana Patients 37

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. 14th at 11:00 a.m.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Veriheal

JULY 12, 2021

According to data on Healthy Place , treatment for PTSD is typically accommodated for the general public, of who the vast majority have not experienced military combat. At this time, there is little in the way for combat-related PTSD treatment specifically. A study conducted by Miriam Reisman reported that between 13.5%

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., Dr. Chapman received his M.D.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JULY 27, 2021

NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S.,

Research and Development 98

Research and Development Pharmaceutical Sativa Extraction 98

Cannabis Law Report

JULY 19, 2021

First-of-its-kind universal milliliter to milligram calculation has potential to transform rapidly growing plant-based medicines sector. This is a precedent-setting experiment that is expected to generate the data needed to facilitate an accurate milligram dosing experience with dry herb.”. billion by 2027. About RYAH Group, Inc.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JUNE 23, 2021

By 2024, the medicinal cannabis market within the United Kingdom is predicted to be worth nearly US$1.3 has emerged as the largest supplier of medicinal cannabis in the world. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle. in real terms to £4.97

Programs 100

Programs Data Events Collective 100

Cannabis Law Report

JANUARY 17, 2022

These molecules belong to the tryptamine class of compounds that has been gaining momentum in the psychedelic medicine space in recent years. Telescope’s synthetic methods are therefore well-poised for compatibility with the standards of current Good Manufacturing Practices (cGMP) ultimately required for pharmaceutical deployment.

Research and Development 52

Research and Development Pharmaceutical Access Medicine 52

Cannabis Law Report

JULY 24, 2019

Dr Mikael Sodergren , Managing Director and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field. But it is important that access to it is delivered in a way that fits in with other treatment options.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Veriheal

DECEMBER 28, 2021

This is according to recent data from a report published by Market Research Future (MRT) – a pioneer in market analysis. “(Cannabis is) also used in conjunction with other medicines, either to improve their efficacy or to mitigate negative side effects. by the year 2027 , at which point the market could be worth a staggering $33.2

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Veriheal

OCTOBER 29, 2020

Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

AUGUST 12, 2021

Since 2013, medicinal cannabis has been legalized in the Czech Republic due to the amendment to the Act on pharmaceuticals, otherwise known as Act No. establishes the criteria for cannabis distributed in pharmacies regarding the prescription, preparation, distribution and use of medicinal goods containing cannabis.

Legalization 59

Legalization Pharmaceutical Safety Extraction 59

Cannabis Law Report

MARCH 22, 2020

A data firm is warning those infected with the novel coronoavirus to avoid consuming products that contain tetrahydrocannabinol (THC), the main psychoactive component of cannabis. Data CEO Julie Armstrong said her company knows the COVID-19 affects the population in a similar way to influenza. The brief survey can be taken here.

THC 59

THC Clinical Trials Data Consumption 59

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Law School.

Therapy 40

Therapy Compliance Compliance Clinical Trials 40

Cannabis Law Report

AUGUST 24, 2019

The report reveals… MGC Pharmaceuticals is set to kick off a controlled trial to discover if its medical cannabis product for the treatment of drug-resistant epilepsy has any impact on driving performance.

Epilepsy 45

Epilepsy Pharmaceutical Data Safety 45

SpeedWeed

AUGUST 11, 2021

“Suicide among veterans is an urgent public health crisis, but it’s solvable if we invest in researching new treatments for pain, depression, and PTSD,” said Sisley in a press statement. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

NOVEMBER 19, 2021

MAPS PBC is pioneering a new form of mental health care, beginning with the development of MDMA-assisted therapy as an FDA-approved treatment for PTSD. MDMA-assisted therapy is a new paradigm in the treatment of mental health, combining a medicine with psychotherapy to address the root causes of PTSD. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Veriheal

APRIL 24, 2023

The body of scientific evidence supporting the use of psychedelics in the treatment of PTSD, addiction, major depressive disorder, and various other mental health disorders continues to grow. However, despite the mounting data supporting their efficacy, the precise mechanism of action for psychedelics remains a mystery.

Research and Development 77

Research and Development Treatment Conditions Therapy 77

SpeedWeed

MARCH 13, 2021

Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. However, common treatments do not address the non-motor symptoms and can sometimes cause side effects including dyskinesia, an abnormality or impairment of voluntary movement. . View original article.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. Frontier Data predicts total sales of all CBD products in the U.S. Frontier Data predicts total sales of all CBD products in the U.S.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51